These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Standard 37: site selection. Gorski LA J Infus Nurs; 2009; 32(3):125-6. PubMed ID: 19444018 [No Abstract] [Full Text] [Related]
43. [Needleless connection valves--commentary from a clinical perspective]. Simon A; Trautmann M Dtsch Med Wochenschr; 2008 Feb; 133(5):206-8. PubMed ID: 18213555 [TBL] [Abstract][Full Text] [Related]
44. Intravenous filters and phlebitis. Francombe P Nurs Times; 1988 Jun 29-Jul 5; 84(26):34-5. PubMed ID: 3405814 [No Abstract] [Full Text] [Related]
45. Toxic chemicals in i.v. tubing. Sattler B; Malkan S N J Nurse; 2005; 35(4):7. PubMed ID: 16173442 [No Abstract] [Full Text] [Related]
46. Heparin vs saline for intermittent intravenous device maintenance in neonates. Kotter RW Neonatal Netw; 1996 Sep; 15(6):43-7. PubMed ID: 8932071 [TBL] [Abstract][Full Text] [Related]
47. Nursing implications of low-dose heparin to infusate to improve infusion site survival in children. Wright A Aust Crit Care; 1993 Dec; 6(4):10-3. PubMed ID: 8136625 [TBL] [Abstract][Full Text] [Related]
48. The Multiport manifold tubing system for delivery of i.v. medications. DeLeon CM Oncol Nurs Forum; 1999 May; 26(4):682. PubMed ID: 10337637 [No Abstract] [Full Text] [Related]
49. There's just no excuse for i.v. complications. Magdziak BJ RN; 1988 Feb; 51(2):30-1. PubMed ID: 3344379 [No Abstract] [Full Text] [Related]
50. Infection risks in i.v. therapy. Crow S NITA; 1987; 10(2):101-5. PubMed ID: 3645339 [No Abstract] [Full Text] [Related]
51. Reducing the risk of complications in i.v. therapy. Dougherty L Nurs Stand; 1997 Oct 22-28; 12(5):40-2. PubMed ID: 9392295 [No Abstract] [Full Text] [Related]
52. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity. Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951 [TBL] [Abstract][Full Text] [Related]
53. Venous anatomy and physiology. Considerations for vascular access device placement and function. Sansivero GE J Intraven Nurs; 1998; 21(5 Suppl):S107-14. PubMed ID: 9814285 [TBL] [Abstract][Full Text] [Related]
55. A comparative study of two securement techniques for short peripheral intravenous catheters. Wood D J Intraven Nurs; 1997; 20(6):280-5. PubMed ID: 9423389 [TBL] [Abstract][Full Text] [Related]
56. [Infusion thrombophlebitis]. Bedük T Turk Hemsire Derg; 1987; 37(1):32-5, 60. PubMed ID: 3660484 [No Abstract] [Full Text] [Related]
57. Access-port complications after laparoscopic gastric banding. Susmallian S; Ezri T; Elis M; Charuzi I Obes Surg; 2003 Feb; 13(1):128-31. PubMed ID: 12630627 [TBL] [Abstract][Full Text] [Related]
58. Should continuous intravenous (i.v.) heparin be infused via a Y site? Eisenberg S Crit Care Nurse; 1999 Jun; 19(3):88. PubMed ID: 10661097 [No Abstract] [Full Text] [Related]
59. Reliability of an intravenous intermittent access port (saline lock) for obtaining blood samples for coagulation studies. Arrants J; Willis ME; Stevens B; Gripkey L; Herman JA; Hernandez-Brooks L; Eaker JE Am J Crit Care; 1999 Sep; 8(5):344-8. PubMed ID: 10467472 [TBL] [Abstract][Full Text] [Related]
60. [Venous catheterization can cause infusion thrombophlebitis. Study of the literature on its causes and occurrence]. Adolfsson A; Luttropp HH Lakartidningen; 1996 Nov; 93(48):4398, 4403-4. PubMed ID: 8992157 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]